Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tucatinib

- PMLiVE

Pfizer breast cancer drug shines in latest trial

Study with Ibrance stopped early because of its success

- PMLiVE

Nektar hit by breast cancer trial setback

NKTR-102 failed to meet phase III targets

- PMLiVE

Pfizer’s Ibrance wins early breast cancer approval in US

FDA’s decision come two months ahead of schedule

- PMLiVE

Double trial disappointment for Roche

Discontinues Alzheimer’s programme and finds Kadcyla no better than Herceptin in certain breast cancer

- PMLiVE

Novartis’ Afinitor fails frontline breast cancer trial

Drug already approved to treat HER2-negative breast cancer

- PMLiVE

Merck to start major trial of Keytruda in breast cancer

PD-1 immunotherapy is already available as treatment for melanoma

- PMLiVE

UK landmarks turn pink for breast cancer

Breast Cancer Campaign encourages people to Wear It Pink

- PMLiVE

Pressure put on Roche to cut Kadcyla’s UK price

30,000 people sign petition to help make the breast cancer drug available on the NHS

- PMLiVE

Eisai launches online breast cancer resource

Website includes information on the disease, treatment options and side effects

- PMLiVE

Pfizer’s palbociclib on track for early 2015 launch

Good news for the highly anticipated breast cancer drug

- PMLiVE

Breast cancer drug market set to double in 10 years

New entrants will join market leaders Roche, Novartis and AstraZeneca

Roche's Perjeta pertuzumab

Roche’s Perjeta should be ‘new standard’ in breast cancer

Could improve survival when added to therapy with Herceptin and docetaxel

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links